Literature DB >> 1696204

Effect of interleukin 3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts.

M Brach1, H Klein, E Platzer, R Mertelsmann, F Herrmann.   

Abstract

The concept of biologic modification of proliferation and differentiation of myeloid leukemia cells has attracted much attention over the past years. One promising strategy involves the recruitment of leukemic cells into the cell cycle by hematopoietic growth factors in combination with cycle-specific cytotoxic drugs. Because cytosine arabinoside (Ara-C), which targets only cells in S-phase of the mitotic cell cycle, is included in most chemotherapeutic regimens for the treatment of acute myelogenous leukemia, we explored the hypothesis that the recruitment of quiescent immature leukemic blasts into the cell cycle by the early acting growth factor interleukin 3 (IL-3) can increase the efficacy of Ara-C for kill of leukemic stem cells. We show that IL-3 increases the fraction of blasts in S-phase, as assessed by DNA histogram analysis with propidium iodide staining, leading to an enhancement of kill of clonogenic blast cells when combined with Ara-C. Expression of the protooncogenes c-myc, c-fms, and c-fos, known to be linked to cellular proliferation and differentiation, was also altered by IL-3 in Ara-C-treated cultures, further substantiating the role that IL-3 plays as an enhancer of the cytotoxicity of Ara-C.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696204

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  5 in total

Review 1.  The role of colony-stimulating factors in acute leukemia.

Authors:  F Herrmann; E Vellenga
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Glyceraldehyde 3-phosphate dehydrogenase depletion induces cell cycle arrest and resistance to antimetabolites in human carcinoma cell lines.

Authors:  Manali S Phadke; Natalia F Krynetskaia; Anurag K Mishra; Evgeny Krynetskiy
Journal:  J Pharmacol Exp Ther       Date:  2009-07-23       Impact factor: 4.030

3.  Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.

Authors:  H H Gerhartz; R Marcus; A Delmer; H Zwierzina; T de Witte; A Jacobs; G Visiani; D Fiere; P Sonneveld; B Labar
Journal:  Infection       Date:  1992       Impact factor: 3.553

4.  In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.

Authors:  N Van der Lely; T De Witte; J Wessels; R Raymakers; P Muus; F Preijers
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

Review 5.  Evolution of the arabinosides and the pharmacology of fludarabine.

Authors:  W Plunkett; V Gandhi
Journal:  Drugs       Date:  1994       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.